References
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824–35.
Torphy R, Friedman C, Ho F, Leonard L, Thieu D, Lewis K, et al. Adjuvant therapy for stage III melanoma without immediate completion lymph node dissection. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10775-8.
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in Melanoma. N Engl J Med. 2017;376(23):2211–22.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Torphy, R.J., McCarter, M.D. & Gleisner, A.L. ASO Author Reflections: Adjuvant Therapy for Stage III Melanoma With or Without Completion Lymph Node Dissection. Ann Surg Oncol 29, 816–817 (2022). https://doi.org/10.1245/s10434-021-10838-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-10838-w